Newsroom

Reuters: UK regulator authorizes GSK's RSV vaccine

Reuters
Written by
Reuters
Published Jul 10, 2023

Important information - investing for longer increases the likelihood of positive returns. Over a period of five years or more, investments usually give you a higher return compared to cash savings. But investments can go down as well as up in value, so you could get back less than you put in. This isn't personal advice. If you’re not sure what's right for you, ask for advice.

Britain's medicines regulator authorized GSK's vaccine for respiratory syncytial virus (RSV) for older adults, the drugmaker said on Monday.

This article is more than 2 years old

It was correct at the time of publishing. Our views and any references to tax, investment, and pension rules may have changed since then.

The Medicines and Healthcare products Regulatory Agency (MHRA) authorised GSK's shot, called Arexvy, for active immunisation to prevent lower respiratory tract disease (LRTD) caused by RSV in adults 60 years and older, the company said.

This article was from Reuters and was legally licensed through the Industry Dive Content Marketplace. Please direct all licensing questions to legal@industrydive.com.